Navigation Links
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
Date:2/1/2010

is is also applying its platform technology to develop products in therapeutic areas beyond vascular disease, such as inflammatory and orthopedic diseases.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

About Vascugel and PVS-10200

Vascugel, a novel, biologically active therapy developed using tissue-engineered allogeneic endothelium, is under investigation for enhancing blood vessel repair and promoting vascular health. In May 2009, Vascugel received an Orphan Drug designation from the U.S. Food and Drug Administration for the prevention of arteriovenous fistula or arteriovenous graft failure in patients with end-stage renal disease

PVS-10200, a biologically active therapy developed using tissue-engineered allogeneic endothelium, is designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions. PAD is a systemic disease in which plaque builds up in arteries, causing the restriction of blood flow that can lead to serious complications, including limb amputation, kidney failure, stroke and death.

About End-stage Renal Disease (ESRD)

End-stage renal disease (ESRD) is an advanced and irreversible condition treated mainly by hemodialysis or kidney transplantation. It is estimated more than 350,000 Americans with ESRD receive hemodialysis each year.(1) Complications following AV access procedures for hemodialysis are common, and an estimated 60 percent of AV grafts fai
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
(Date:12/24/2014)... 2014 PuraMed BioScience®, Inc., (OTC Pink: PMBS), ... and healthcare products, announced it received the initial funding ... advanced headache relief product, for planned distribution to 1,000 ... , Washington State , and ... MigraPure H Advanced headache relief gel formulation completed, PuraMed ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... , , FRAZER, Pa., Jan. 8 Cephalon, Inc., (Nasdaq: ... Robert P. Roche, Jr., Executive Vice President of Worldwide Pharmaceutical ... other longstanding interests. During his tenure, Mr. Roche established ... global business that exceeded $2 billion in annual sales revenue. ...
... , RIDGEWOOD, N.J., Dec. 31 Women,s Digital Imaging of ... a technology developed to screen for osteoporosis (bone loss), to ... method of establishing goals and measuring results for weight management ... been a standard measuring tool, it does not distinguish muscle ...
Cached Medicine Technology:Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 2Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 3Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position 4Women's Digital Imaging Using DXA Total Body Fat Analysis to Help Patients in Weight Management and Fitness Programs 2
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... News) -- Overeating is common during the holidays, but there ... expert says. "Don,t arrive at a party hungry. It ... you,ll be attending a party, but deprivation leads to hunger, ... Northern Westchester Hospital in Mount Kisco, N.Y., said in a ... the day and even to have a snack before attending ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... 18 PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH), ... that it has raised $24.4 million in a ... value $0.00001 per share, to accredited investors at ... an approximate 17% discount to the average closing price of ...
... FREMONT, Calif. , March 18 Velos, Inc., the recognized ... Kamar Aulakh has joined the company to serve as Chief Operating ... in technology and healthcare. In his role as COO, he will oversee all ... ...
... ... AIDS Foundation today announced that Dr Megan Dunbar has been appointed ... 5. Pangaea Global AIDS Foundation helps countries, heavily affected by ... with a particular focus on hard-to-reach vulnerable populations, including women and ...
... ClinAudits, ... quality remediation solutions for the pharmaceutical, medical device, biotechnology, and tissue engineering industries, announced ... , ... (PRWEB) March 18, 2010 -- ClinAudits , LLC, an independent, 3rd party ...
... that blocking a certain protein can reduce or ... underlies the disease process of chronic obstructive pulmonary ... The findings have been published online ahead ... American Journal of Respiratory and Critical Care ...
... ST. LOUIS , March 17 Centene Corporation (NYSE: CNC ) announced today that one of its subsidiaries, Cenpatico Behavioral Health of Arizona (Cenpatico), ... ... ... ...
Cached Medicine News:Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 2Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 3Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 4Health News:Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer 2Health News:Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer 3Health News:Kamar Aulakh Joins Velos, Inc. as Chief Operating Officer 4Health News:Megan Dunbar Named VP of Programs for Pangaea Global AIDS Foundation 2Health News:ClinAudits Joins Bioanalytical Quality Standards Initiative (BQSI) Expert Working Group 2Health News:ClinAudits Joins Bioanalytical Quality Standards Initiative (BQSI) Expert Working Group 3Health News:New technique reduces tobacco smoke damage to lungs in mice 2Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 2Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 3Health News:Centene's Arizona Behavioral Health Unit Awarded Expanded Contract 4
... latest 3-part differential analyzer based on the ... the CELL-DYN line. Offering 18 parameters and ... CELL-DYN 1800 meets the needs to today's ... than its predecessors and fits under standard ...
... produces high-quality blood films. Smearing parameters have ... time, eliminating the need to make adjustments ... hematocrit values. In the closed sampling mode, ... and aspirates only 200L. Only 30L of ...
... InstaCheck® Menopause Predictor Test is an in ... FSH in urine. Changes in FSH levels ... symptoms associated with stages of menopause. The ... obtain a visual, qualitative result and is ...
... diabetes continue to have a tremendous impact ... of patients, in addition to the significant ... be associated with elevated levels of blood ... haemoglobin A1c (HbA1c) in a diabetic patient's ...
Medicine Products: